Table 1 Clinical characteristics of study population at the age of 50 years
From: Contribution of syndecan-4 genetic variants to hypertension, the TAMRISK study
Cases (n = 279) | Controls (n = 488) | P | |
|---|---|---|---|
Age (years) | 50 ± 0 | 50 ± 0 | |
Gender (male) % | 64 | 62 | 0.699 |
Body mass index (kg/m2) | 28.8 ± 5.2 | 25.9 ± 4.0 | <0.000 |
Cholesterol (mmol/l) | 5.41 ± 1.08 | 5.39 ± 0.88 | 0.769 |
Glucose (mmol/l) | 5.24 ± 1.40 | 4.85 ± 0.52 | <0.000 |
Systolic blood pressure (mm Hg) | 142.4 ± 16.4 | 131.3 ± 15.9 | <0.000 |
Diastolic blood pressure (mm Hg) | 92.3 ± 8.6 | 85.8 ± 9.8 | <0.000 |
Exercise (at least twice a week) % | 36.0 | 30.0 | 0.090 |
Diabetes % | 8.0 | 0 | <0.000 |
Myocardial infarction % | 6.0 | 0 | <0.000 |
Coronary artery disease % | 11.0 | 0 | <0.000 |
Syndecan-4 rs4599 (CC/TC/TT) % | 4.4/36.1/59.5 | 3.3/37.6/59.1 | 0.717 |
Syndecan-4 rs1981429 (GG/TG/TT) % | 22.4/48.0/29.6 | 25.4/53.3/21.3 | 0.017 |